News from bayer healthcare A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 08, 2013, 02:30 ET

Bayer's Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

 Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for...

Mar 25, 2013, 17:16 ET

Bayer's Stivarga® (regorafenib) Tablets Approved in Japan

 Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the Ministry of Health, Labor and Welfare (MHLW) in...

Mar 05, 2013, 10:00 ET

Bayer HealthCare Enters into Distribution Agreement to Expand Markets for the Medrad™ Intego™ PET Infusion System

 Bayer HealthCare is expanding its global distribution network for the Medrad™ Intego™ PET Infusion System through a new...

Mar 01, 2013, 08:05 ET

Fight Colorectal Cancer Battles Cancer at One of the Busiest Attractions in the World

Intended for U.S. Media Only --  Fight Colorectal Cancer, the United States' leading colorectal cancer advocacy organization,...

Feb 25, 2013, 16:05 ET
Second FDA approval for Bayer oncology drug.  (PRNewsFoto/Bayer HealthCare Pharmaceuticals Inc.)

Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST

 Intended for U.S. Media Only -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and...

Feb 13, 2013, 01:00 ET

U.S. FDA Grants Priority Review to Bayer's Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases

 Bayer HealthCare announced today that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223...

Feb 11, 2013, 07:51 ET

Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking...

Jan 21, 2013, 08:00 ET

Bayer-AAFP study finds 78 percent of veterinarians see cat care as key to practice growth, but many are slow to make practices more cat-friendly

 A new study conducted by Bayer HealthCare, in collaboration with the American Association of Feline Practitioners (AAFP), reveals that 78...

Jan 20, 2013, 08:00 ET

Bayer HealthCare Introduces Seresto™, Offering Easy-To-Use Flea and Tick Control for Dogs or Cats that Lasts Eight Months

 Bayer HealthCare LLC Animal Health Division today announced the launch of Seresto, an effective, eight-month tick and flea...

Jan 10, 2013, 13:10 ET

Video Now Available: U.S. FDA Approves Bayer's Skyla™ (Levonorgestrel-Releasing Intrauterine System) 13.5 mg For Prevention Of Pregnancy For Up To Three Years

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Skyla™...

Jan 09, 2013, 16:15 ET
U.S. FDA Approves Bayer's Skyla(TM) (levonorgestrel-releasing intrauterine system) 13.5 mg.  (PRNewsFoto/Bayer HealthCare)

U.S. FDA Approves Bayer's Skyla™ (Levonorgestrel-Releasing Intrauterine System) 13.5 mg For Prevention Of Pregnancy For Up To Three Years

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Skyla™...

Jan 09, 2013, 08:00 ET

Accuracy can be as EZ as 1, 2, 3 for patients managing their diabetes

New CONTOUR® NEXT EZ Strip and Meter Combination is accurate and easy to use TORONTO, Jan. 9, 2013 /CNW/ - A new, accurate and easy-to-use...

Jan 03, 2013, 09:00 ET
Bayer HealthCare LLC.  (PRNewsFoto/Bayer HealthCare LLC)

Bayer HealthCare completes acquisition of Teva Pharmaceutical Industries' U.S. animal health business

 Bayer HealthCare LLC announced today that it has received the necessary regulatory approvals to complete the acquisition of the U.S.-based...

Jan 03, 2013, 02:30 ET

Phase 3 DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial of Nexavar® (sorafenib)...

Dec 14, 2012, 08:01 ET

Bayer Submits New Drug Application for Radium Ra 223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases

 Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...

Dec 07, 2012, 15:29 ET

Bayer Consumer Care Voluntarily Recalls 56 Lots of BRONKAID Caplets Dual Action Formula due to Product Labeling Error

 In consultation with the U.S. Food and Drug Administration (FDA), Bayer HealthCare's Consumer Care division has begun a voluntary recall of...

Dec 05, 2012, 09:00 ET
New from the Dermatology Unit of Bayer HealthCare: The Eczema App.  (PRNewsFoto/Bayer HealthCare)

New Survey Finds Moms Are Under-Informed about Children's Eczema and Seek New Digital Tools to Help Fill Void

Bayer HealthCare, in partnership with Mom Central Consulting, announced findings from a recent survey indicating that three-quarters (76 percent)...

Dec 05, 2012, 08:00 ET

"Cat Myth Busters" share "how-tos" of winterizing your pet

 Since ancient times, cats have been misunderstood, leading to many false feline myths. Some are harmless, like cats can't get along with dogs;...

Nov 29, 2012, 09:00 ET

Bayer HealthCare Introduces Resultix™, a New Tick Killing Solution for Dogs and Cats

Today, Bayer HealthCare LLC Animal Health Division made it easy to kill ticks on dogs and cats with Resultix, a new, simple spray-on formula that...

Nov 28, 2012, 03:15 ET

Bayer Announces Recruitment Achievement for Investigational Hemophilia Treatment

Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the...